News

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief ...
clinicaladvisor.com2mon
Tau-Targeting Antisense Therapy for Alzheimer Disease Gets Fast Track Status
Patients treated with high-dose BIIB080 saw positive trends on the global Clinical Dementia Rating Sum of Boxes, Mini-Mental State Exam cognitive scales and Functional Activities Questionnaire at ...
The Globe and Mail2mon
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational ...
Taiwan News2mon
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...
Seeking Alpha2mon
Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status
Biogen (NASDAQ:BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense oligonucleotide therapy targeting tau for Alzheimer’s disease treatment.
Investing2mon
Biogen’s BIIB080 gains FDA fast track for Alzheimer’s
BIIB080 is an antisense oligonucleotide (ASO) therapy targeting tau, a protein associated with neurodegeneration in Alzheimer’s disease. It is the first tau-targeting ASO to enter clinical development ...
MarketWatch2mon
Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
Biogen has won a U.S. Food and Drug Administration fast-track designation for its investigational BIIB080 therapy for the treatment of Alzheimer's disease. Biogen on Wednesday said BIIB080 is the ...